Author Index for Volume 8

Andersen PK, 67
Atkinson EN, 29
Azen SP, 354

Baglivo J, 243
Begg CB, 121
Bissett JK, 136
Blankenhorn DH, 354
Blessing JA, 60
Brown BW, 29
Brown BW Jr, 177
Brown ER, 243
Bundy BN, 60

Canner PL, 1
Case LD, 146
Chalmers I, 388
Chalmers TC, 343
Chan S, 343
Charboneau A, 190
CLAS Investigators and Staff, 354
Curb JD, 110

Dantes R, 12
Davis BR, 110
Davis CE, 146
Detre K, 190
Dickersin K, 343
Dyrda I, 216

Edler L, 45
Ehrman S, 110

Farmer J, 110
Foulkes MA, 315
Freedman D, 216
Fye CL, 101

Gatewood LC, 1
Goldman AI, 327
Gosselin G, 216

Haakenson C, 101
Hache M, 216
Halloran J, 216
Halperin M, 315
Halpern J, 177
Hamersma, EAM, 96
Hatch HT, 190
Havel RJ, 216
Hawkins BS, 75, 158, 255, 395
Hawkins CM, 110
Haynes RB, 12
Heiselbetz C, 45
Herson J, 29
Hudon G, 216

Johnson G, 190
Johnson RL, 354
Joyal M, 216

Kalish LA, 121
Kamm B, 216
Karnegis JN, 136
Krishnamoorthy KC, 243
Kuban KCK, 243

Lachin JM, 1
Lan KKG, 315
Langley GR, 49
Lemarbre L, 216
Leon AS, 136
Lesperance J, 216
Leviton A, 243
Llewellyn-Thomas HA, 49
Long JM, 136

Martin M, 110
Matts JP, 136
Minkin S, 49
Morgan TM, 146

Nessim SA, 354

Patterson BH, 87, 202
Peduzzi P, 190
Phillips M, 338
Piantadosi S, 202
Priore RL, 60
Pritchett J, 190

Reese PA, 60
Rozell ME, 29

Sacks HS, 343
Sanmarco ME, 354
Sather MR, 101
Sawin HS, 136
Schoenfield LJ, 1
Selzer RH, 354
Siers A, 96
Silverman W, 388
Slagle JR, 136
Smith H Jr, 343
Stevenson JP, 136
Sutherland HJ, 49

Therneau T, 20
Theroux P, 216
Till JE, 49
Toussaint DJ, 101
Tung B, 110

van der Putten E, 96
van der Velden JW, 96
Vazquez AJ, 338

Waters D, 216
White C, 1
Wick MW, 136
Wieand S, 20
Wong S, 49
Wright EC, 315

© Elsevier Science Publishing Co., Inc. 1987
52 Vanderbilt Ave., New York, New York 10017

0197-2456/87/$3.50

Subject Index for Volume 8

ABNORMAL FINDINGS IN "NORMAL" VOLUNTEERS
Abnormal Findings in "Normal" Research Volunteers, 338

ACCRUAL
A Method for Predicting Accrual, Cost, and Paper Flow in Clinical Trials, 202

APL
A Sample Size Program for "Proving the Null Hypothesis," 45

ARCSIN STATIC
A Two-Stage Design for Randomized Trials with Binary Outcomes, 20

BAYESIAN METHODS
Projection from Previous Studies: A Bayesian and Frequentist Compromise, 29

BENEFICIARY IDENTIFICATION
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Artery Bypass Surgery, 190

BINOMIAL RESPONSE
A Two-Stage Design for Randomized Trials with Binary Outcomes, 20

BOOK REVIEWS
A Classified Bibliography of Controlled Trials in Perinatal Medicine, 1940–1984 by the National Perinatal Epidemiology Unit (Oxford, England), 85
Clinical Epidemiology. The Architecture of Clinical Research by Feinstein AR, 404
Clinical Trials: Design, Conduct, and Analysis by Meinert CL in collaboration with Tonascio S, 406
The Quality of Life of Cancer Patients, Aaronson NK and Beckmann J (eds.), 409

CANCER CLINICAL TRIAL
A Pilot Study on the Quality of Data Management in a Cancer Clinical Trial, 96

CENSORED SURVIVAL DATA
Conditional Power Calculations as an Aid in the Decision Whether to Continue a Clinical Trial, 67

CENTRALIZED FOLLOW-UP
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Bypass Surgery, 190

CLINICAL EXPERIMENTATION
Professional and Public Double Standards on Clinical Experimentation, 388

CLINICAL JUDGMENT
An Example of Expert Systems Applied to Clinical Trials: Analysis of Serial Graded Exercise ECG Test Data, 136

CLINICAL TRIALS
Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results, The, 354
Example of Expert Systems Applied to Clinical Trials: Analysis of Serial Graded Exercise ECG Test Data, An, 136
Experience with the Use of Generalized Data Base Management Systems in Cooperative Group Clinical Trials (A Project of the Gynecologic Oncology Group), 60
External Monitoring of a Data Coordinating Center: Experience of the National Cooperative Gallstone Study, 1
Investigator-Sponsored IND in Clinical Trials, The, 101
Method for Predicting Accrual, Cost, and Paper Flow in Clinical Trials, A, 202
Optimal Restricted Two-Stage Designs, 146
Patient Compliance and the Conduct and Interpretation of Therapeutic Trials, 12
Prophylactic Clinical Trial as an Epidemiologic Resource, The, 243
Stochastic Curtailing for Comparison of Slopes in Longitudinal Studies, 315

0197-2456/87/$3.50

© Elsevier Science Publishing Co., Inc. 1987
52 Vanderbilt Ave., New York, New York 10017

Why Are (or Are Not) Patients Given the Option to Enter Clinical Trials?, 49

CLINICAL TRIAL DESIGN
Designing Clinical Trials with Arbitrary Specification of Survival Functions and for the Log Rank or Generalized Wilcoxon Test, 177

CODING CAUSE OF DEATH
Standardized Physician Preparation of Death Certificates, 110

COMMENTARY
Professional and Public Double Standards on Clinical Experimentation, 388

COORDINATING CENTER
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Artery Bypass Surgery, 190

COMPUTER PROGRAM
A Sample Size Program for "Proving the Null Hypothesis," 45

COMPUTERIZED ASSESSMENT OF ATHEROSCLEROSIS
The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results, 354

CONDITIONAL CONFIDENCE INTERVALS
Conditional Power Calculations as an Aid in the Decision Whether to Continue a Clinical Trial, 67

COOPERATIVE GROUP
Experience with the Use of Generalized Data Base Management Systems in Cooperative Group Clinical Trials (A Project of the Gynecologic Oncology Group), 60

CORONARY ANGIOGRAPHY
The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results, 354

CORONARY ARTERY DISEASE
Design Features of a Controlled Clinical Trial To Assess the Effect of A Calcium Entry Blocker Upon the Progression of Coronary Artery Disease, 216

COST
A Method for Predicting Accrual, Cost, and Paper Flow in Clinical Trials, 202

COST MODEL
The Impact of Screening and Eliminating Preexisting Cases on Sample Size Requirements for Cancer Prevention Trials, 87

CURE RATE MODEL
Designing Clinical Trials with Arbitrary Specification of Survival Functions and for the Log Rank or Generalized Wilcoxon Test, 177

DATA ANALYSIS
An Example of Expert Systems Applied to Clinical Trials: Analysis of Serial Graded Exercise ECG Test Data, 136

DATA COORDINATING CENTER
External Monitoring of a Data Coordinating Center: Experience of the National Cooperative Gallstone Study, 1

DATA MANAGEMENT
A Pilot Study on the Quality of Data Management in a Cancer Clinical Trial, 96

DATABASE MANAGEMENT SYSTEM
Experience with the Use of Generalized Data Base Management Systems in Cooperative Group Clinical Trials (A Project of the Gynecologic Oncology Group), 60

DEATH CERTIFICATES
Standardized Physician Preparation of Death Certificates, 110

DESIGN
A Sample Size Program for "Proving the Null Hypothesis," 45

EPIDEMIOLOGY
The Prophylactic Clinical Trial as an Epidemiologic Resource, 243

EQUIVALENCE TESTING
A Sample Size Program for "Proving the Null Hypothesis," 45

ETHICS
Why Are (or Are Not) Patients Given the Option to Enter Clinical Trials?, 49

EXPERT SYSTEMS
An Example of Expert Systems Applied to Clinical Trials: Analysis of Serial Graded Exercise ECG Test Data, 136

FEMORAL ANGIOGRAPHY
The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results, 354

FOOD AND DRUG ADMINISTRATION
The Investigator-Sponsored IND in Clinical Trials, 101

GENERALIZED WILCOXON TEST
Designing Clinical Trials with Arbitrary Specification of Survival Functions and for the Log Rank or Generalized WilcoxonTest, 177

IND
The Investigator-Sponsored IND in Clinical Trails, 101

INVESTIGATOR
The Investigator-Sponsored IND in Clinical Trials, 101

LINEAR REGRESSION
Stochastic Curtailing for Comparison of Slopes in Longitudinal Studies, 315

LITERATURE
Perusing the Literature, 75, 158, 255, 395

LOG RANK TEST
Designing Clinical Trials with Arbitrary Specification of Survival Functions and for the Log Rank or Generalized Wilcoxon Test, 177

LOGISTIC MODEL
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias, 121

MATHEMATICAL MODELS
A Method for Predicting Accrual, Cost, and Paper Flow in Clinical Trials, 202

META-ANALYSIS
Publication Bias and Clinical Trials, 343

MONITORING
External Monitoring of a Data Coordinating Center: Experience of the National Cooperative Gallstone Study, 1

NOMINAL SIGNIFICANCE LEVEL
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias, 121

NOSOLOGICAL CODING
Standardized Physician Preparation of Death Certificates, 110

ONCOLOGY
Why Are (or Are Not) Patients Given the Option to Enter Clinical Trials?, 49

PATIENT COMPLIANCE
Patient Compliance and the Conduct and Interpretation of Therapeutic Trials, 12

PATIENT TREATMENT FILE
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Artery Bypass Surgery, 190

PERMUTATION TEST
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias, 121

PREVENTION
The Prophylactic Clinical Trial as an Epidemiological Resource, 243

PREVENTION TRIAL
The Impact of Screening and Eliminating Preexisting Cases on Sample Size Requirements for Cancer Prevention Trials, 87

PUBLICATION BIAS
Publication Bias and Clinical Trials, 343

QUALITY CONTROL
A Pilot Study on the Quality of Data Management in a Cancer Clinical Trial, 96

RANDOM ALLOCATION
Patient Compliance and the Conduct and Interpretation of Therapeutic Trials, 12

RANDOMIZATION
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias, 121

RANDOMIZED CLINICAL TRIALS
Publication Bias and Clinical Trails, 343

RECORDS LOCATOR SUBSYSTEM
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Bypass Surgery, 190

SAMPLE SIZE
Impact of Screening and Eliminating Preexisting Cases on Sample Size Requirements for Cancer Prevention Trails, The, 87
Optimal Restricted Two-Stage Designs, 146
Projection from Previous Studies: A Bayesian and Frequentist Compromise, 29
Sample Size Program for "Proving the Null Hypothesis," A, 45

SCREENING
The Impact of Screening and Eliminating Preexisting Cases on Sample Size Requirements for Cancer Prevention Trials, 87

SEQUENTIAL STOPPING RULES
Issues in Designing Sequential Stopping Rules for Monitoring Side Effects in Clinical Trials, 327

SIDE EFFECTS
Issues in Designing Sequential Stopping Rules for Monitoring Side Effects in Clinical Trials, 327

SOCIETY FOR CLINICAL TRIALS
Abstracts: Eighth Annual Meeting Society for Clinical Trails, 280
Final Program: Eighth Annual Meeting Society for Clinical Trials, 267
Society for Clinical Trials Officers, Board of Directors, Program Committee, and Secretariat, 266

SPONSOR
The Investigator-Sponsored IND in Clinical Trials, 101

STOCHASTIC CURTAILING
Stochastic Curtailing for Comparison of Slopes in Longitudinal Studies, 315

STOCHASTICALLY CURTAILED TESTING
Conditional Power Calculations as an Aid in the Decision Whether to Continue a Clinical Trial, 67

STOPPING RULE
A Two-Stage Design for Randomized Trials with Binary Outcomes, 20

STUDY PLANNING
Projection from Previous Studies: A Bayesian and Frequentist Compromise, 29

TREATMENT ALLOCATION
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias, 121

TREATMENT OF ATHEROSCLEROSIS
The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results, 354

TWO-STAGE DESIGN
Optimal Restricted Two-Stage Designs, 146

VALIDITY
Patient Compliance and the Conduct and Interpretation of Therapeutic Trials, 12

VALUE ASSESSMENTS
Why Are (or Are Not) Patients Given the Option to Enter Clinical Trials?, 49